Albitar, Maher

Publishing since 1992 (Senior)

Has published 129 publications in 18 years

Number of publications published per year by Albitar, Maher. (Source : PubMed)

Distribution of publications types for Albitar, Maher. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.  Blood  2009;114;24  
•  Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.  Blood  2009;114;19  
•  Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.  J. Clin. Oncol.  2009;27;28  
•  Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.  J. Clin. Oncol.  2009;27;23  
•  Rytting ME, Kantarjian H, Albitar M. Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity.  Am. J. Clin. Pathol.  2009;132;2  
•  Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.  Clin. Cancer Res.  2009;15;11  
•  Lee TS, Potts SJ, Albitar M. Basis for resistance to imatinib in 16 BCR-ABL mutants as determined using molecular dynamics.  Recent patents on anti-cancer drug discovery  2009;4;2  
•  Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.  Cancer Res.  2009;69;9  
•  Lee TS, Ma W, Zhang X, Giles F, Kantarjian H, Albitar M. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.  Cancer  2009;115;8  
•  Albitar M, Yeh C, Ma W. K-ras mutations and cetuximab in colorectal cancer.  N. Engl. J. Med.  2009;360;8  

[ See timeline ] [ See all publications ]